 Tiziana Life Sciences PLC NASDAQ:TLSA, LON:TILS has appointed a vice-president of regulatory affairs. Dr Kevin Shutz, who has 19 years pharma industry experience, 14 of them in the regulatory field, will lead clinical trial interactions with drug watchdogs in the US, Europe and Asia. 